Drugs / HER-2-targeting CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02547961 | Sep 2015 → Aug 2016 | breast cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-11-04 | BrightPath Biotherapeutics | Results HER2 CAR-T細胞の非臨床試験データをSITC 2023で発表します brightpathbio.com ↗ |
| 2022-05-16 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 phiopharma.com ↗
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new preclinical data showing that silencing BRD4 with PH-894, a self-delivering RNAi INTASYL compound, can be used to improve the characteristics of CAR-T cell products during the activation and expansion phases of the cell manufacturing process. |
| 2022-04-11 | BrightPath Biotherapeutics | Results BP2301(HER2 CAR-T細胞療法)の固形がんを対象とした非臨床研究成果について AACR 2022で発表しました brightpathbio.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-04 | BrightPath Biotherapeutics | HER2 CAR-T細胞の非臨床試験データをSITC 2023で発表します brightpathbio.com ↗ |
| 2022-05-16 | Phio Pharmaceuticals Inc. | Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 phiopharma.com ↗ |
| 2022-04-11 | BrightPath Biotherapeutics | BP2301(HER2 CAR-T細胞療法)の固形がんを対象とした非臨床研究成果について AACR 2022で発表しました brightpathbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2-targeting CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02547961 ↗ |
| Known as | HER2-CAR-T | “The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.” NCT02547961 ↗ |
| Modality | Cell therapy | “Autologous T cells will be gene-engineered with the CAR gene using a retrovirus vector.” NCT02547961 ↗ |
| Route | Other | “HER-2-targeting CAR T Cells infusion” NCT02547961 ↗ |